

1 **Title:** Prognostic value of an integrated human papilloma virus and immunoscore model to
2 predict survival in vulva squamous cell carcinoma

3

4 Rammah Elnour¹, Ingjerd Helstrup Hindenes², Malene Færevaaag², Ingrid Benedicte Moss
5 Kolseth³, Liv Cecilie Vestrheim Thomsen^{3,4}, Anne Christine Johannessen^{1,5}, Daniela Elena
6 Costea^{1,5}, Line Bjørge^{3,4*}, Harsh Nitin Dongre^{1#*}

7

8 ¹Center for Cancer Biomarkers CCBIO and Gade Laboratory of Pathology, Department of
9 Clinical Medicine, University of Bergen, Bergen, Norway. ²Department of Chemistry,
10 University of Bergen, Bergen, Norway. ³Department of Obstetrics and Gynecology, Haukeland
11 University Hospital, Bergen, Norway. ⁴Center for Cancer Biomarkers CCBIO, Department of
12 Clinical Science, University of Bergen, Bergen, Norway. ⁵Department of Pathology, Laboratory
13 Clinic, Haukeland University Hospital, Bergen, Norway.

14

15 *These authors contributed equally.

16

17 #Corresponding author: harsh.dongre@uib.no

18 Jonas Lies Vei 65, Department of Clinical Medicine, University of Bergen, 5021 Norway

19

20 Running title: Prognostic impact of immunoscore in VSCC

21

22 Keywords: immunoscore, prognostic marker, vulva squamous cell carcinoma, immune-
23 oncology, digital pathology

24 **Abstract:**

25 **Background:** While the prognostic value of immune-related biomarkers is well characterized in
26 many solid tumors, their significance in vulva squamous cell carcinoma (VSCC) remains unclear.
27 Here, we report a comprehensive analysis of programmed death-ligand 1 (PD-L1) and immune
28 cell infiltrates in VSCC and establish immunoscore models for classification of the disease.

29
30 **Methods:** Archival tissues, immunohistochemistry, and digital quantification were used to
31 investigate the number of CD4+, CD8+, CD68+, CD14+, FoxP3+, and PD-L1+ cells in epithelial
32 and stromal compartments of VSCC ($n=117$). Immunoscores were developed using these
33 parameters and applying the least absolute shrinkage and selection operator (LASSO) to identify
34 predictors of survival. Immunoscores were integrated with HPV status, as determined by mRNA
35 *in situ* hybridization, to construct internally validated nomograms. The models were assessed using
36 Harrell's concordance-index (c-index), calibration plots, Kaplan-Meier curves, and decision curve
37 analysis.

38
39 **Results:** Advanced VSCC (FIGO stage III/IV) was characterized by high numbers of CD68+
40 macrophages and PD-L1+ cells (Spearman's correlation, $\rho>0.80$) in the epithelium. PD-L1 status
41 independently predicted poor progression free survival (PFS) (HR=1.80, (95% CI (1.024-3.170),
42 $p=0.041$). High stromal CD68+ or CD14+ myeloid cell infiltration was associated with poor PFS
43 and disease specific survival (DSS) ($p<0.05$). Immunological parameters were used to determine
44 immunoscores. Immunoscore^{PFS} and immunoscore^{DSS} were independent prognosticators of PFS
45 ($p=0.001$) and DSS ($p=0.007$) respectively. Integrating immunoscores with HPV status (IS-HPV
46 index) improved the prognostic impact of the models. The c-index of IS-HPV index^{PFS} was 0.750

47 for prediction of PFS compared to 0.666 for HPV status and 0.667 for immunoscore^{PFS}. The c-
48 index of IS-HPV index^{DSS} was 0.752 for predicting DSS compared to 0.631 for HPV status and
49 0.715 for immunoscore^{DSS}.

50

51 **Conclusion:** In summary, an index based on HPV status and an immunoscore built on PD-L1
52 expression and immune cell infiltrates could potentially serve as a prognostic tool to refine risk
53 stratification in VSCC. Further validation is warranted to demonstrate clinical utility.

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70 WHAT IS ALREADY KNOWN ON THIS TOPIC

71 Immunoscores have emerged as promising biomarkers in several solid tumors, however the
72 prognostic potential of these models in vulva squamous cell carcinoma (VSCC) remains
73 unexplored. Immunoscores are traditionally based on quantification of CD3+ and CD8+ T
74 lymphocytes within the tumor core and invasive margin. However recent studies have highlighted
75 the prognostic significance of additional immune cell subtypes, such as macrophages, in predicting
76 patient survival. Advanced quantitative methods that enable the determination of immunoscores,
77 incorporating expression of immune checkpoint proteins and infiltration of various immune cell
78 populations within tumors, warrant further investigation.

79

80 WHAT THIS STUDY ADDS

81 This study investigates PD-L1 expression and distinct T lymphocyte and myeloid cell subsets
82 within the spatial architecture of VSCC to identify immunological markers with prognostic value.
83 Computational analysis identified PD-L1+ cells, CD8+ T lymphocytes, FoxP3+ T lymphocytes,
84 and CD14+ myeloid cells as significant survival predictors in VSCC, leading to the development
85 of immunoscores. These immunoscores demonstrated superior predictive performance compared
86 to the individual parameters used to construct the models. Moreover, integrating immunoscores
87 with HPV status and constructing, for the first time, an immunoscore-HPV index nomogram
88 enhanced the prognostic accuracy and net benefit of the models.

89

90 HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

91 The immunoscore-HPV index proposed in this study holds potential as a rapid diagnostic tool to
92 enhance risk stratification in VSCC and facilitate the identification of patients who may benefit

93 from less aggressive treatment approaches. Incorporating immunoscores with clinicopathological
94 or molecular features linked to carcinogenesis in prognostic models could improve classification
95 strategies in VSCC and other cancer types.

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116 Introduction

117 Vulvar squamous cell carcinoma (VSCC) is a relatively rare but heterogenous disease, with 47,300
118 new cases and 18,600 deaths globally each year (1). VSCC accounts for six percent of all
119 gynecological malignancies (2), and its incidence rates have been increasing steadily (3). Despite
120 recent surgical advances, 12-37% of VSCC patients experience disease recurrence, with a five-
121 year survival rate ranging between 30-60% (4, 5). For metastatic disease, the five-year survival
122 rate is reported to be below 30% (6). Beyond surgical resection and radiochemotherapy, treatment
123 options are limited, especially for managing advanced stage disease (7). While precision medicine
124 guided by molecular subtyping has been adopted in various cancers, efforts to incorporate
125 molecular risk stratification in VSCC have only recently begun. VSCC is characterized by two
126 distinct etiopathogenic pathways: high risk human papilloma virus (HPV)-associated VSCC,
127 driven by the integration of the HPV genome and the expression of the E6/E7 oncoproteins, and
128 HPV-independent VSCC which often arises in the context of inflammatory vulvar lesions such as
129 lichen sclerosus (8, 9). Studies have shown that HPV-associated VSCC has better prognosis
130 compared to the more common HPV-independent VSCC (10, 11). Thus, identifying biomarkers
131 to predict survival especially in HPV-independent VSCC is urgently needed.

132
133 The cancer immune contexture, encompassing the infiltration of various immune cell populations
134 and the expression of immune checkpoint proteins (12), is currently being analyzed to identify
135 biomarkers with predictive and prognostic potential in several gynecological cancers (13).
136 Targeting programmed cell death protein-1 (PD-1) with an immune checkpoint inhibitor, has been
137 associated with prolonged survival in a subset of patients with advanced, recurrent, or metastatic
138 VSCC (14). This suggests that modulating the tumor immune microenvironment (TIME) is a

139 viable therapeutical strategy with significant impact on survival, however immunotherapy has not
140 yet been included into standard treatment regimens. Furthermore, the prognostic value of immune
141 checkpoints and specific immune cell subsets within the spatial architecture of VSCC remains
142 unclear (15-18). Recently, studies have indicated that the TIME can be leveraged to establish
143 cancer classification strategies with clinical utility. Indeed, the immunoscore became the first
144 standardized consensus assay for classifying hot and cold tumors based on the infiltration of CD3+
145 and CD8+ T lymphocytes in the tumor core and invasive margin in colon cancer (19-21). There
146 have only been a few studies focused on establishing prognostic models, such as nomograms,
147 capable of stratifying VSCC patients and predicting survival. To our knowledge, immunoscore
148 models based on spatially resolved immunological features have yet to be reported for this disease.
149 Developing prognostic tools based on compartment-specific infiltration patterns of immune cell
150 subsets in both HPV-associated and HPV-independent tumors may enhance personalized medicine
151 and allow for individual risk stratification of VSCC.

152
153 In this study, we report a comprehensive *in-situ* analysis of PD-L1 expression and distinct T
154 lymphocyte- and myeloid cell populations in VSCC, revealing components of the immune
155 landscape associated with disease progression. Using these immunological features, we
156 established a novel immunoscore model for VSCC. Further, we integrated the immunoscore with
157 HPV status and assessed the prognostic value of the resulting immunoscore-HPV status index in
158 predicting risk progression in VSCC.

159
160
161

162 Materials and Methods

163 Study population

164 One hundred and thirty-eight patients diagnosed with VSCC and undergoing treatment at
165 Haukeland University Hospital (HUS), Bergen, Norway between 1999-2017 were included in this
166 retrospective study. The patients were treatment naïve, prospectively sampled, and staged
167 according to the FIGO (International Federation of Gynecology and Obstetrics) criteria. Written
168 consent was obtained from all participants prior to inclusion. Most of the patients were registered
169 in Bergen Gynecologic Cancer Biobank (GYNCAN). A few tumor samples were obtained from
170 the diagnostic biobank at the Department of Pathology (HUS). Cases with missing sample,
171 insufficient epithelial and/or stromal tissue material, neoadjuvant treatment, or withdrawn consent
172 were excluded from this study ($n = 21$). Clinicopathological data were extracted from medical
173 journals as previously described (10). This study was approved by the Regional Committee for
174 Medical and Health Research Ethics Norway (REK Nos: 2017/279 and 2014/1907).

175

176 Sample collection and tissue microarray construction

177 Archival formalin-fixed paraffin embedded (FFPE) sections were hematoxylin and eosin stained
178 to select the areas for construction of tissue microarrays (TMA). A minimum of two 1 mm cylinder
179 biopsies from the tumor front areas of primary tumors, recurrences, and metastases were punched
180 out and placed in paraffin blocks using a precision instrument (Beecher Instruments, Silver Spring,
181 MD, USA). TMA sections of 4- μ m thickness were cut using a microtome (Leica Microsystems,
182 Wetzlar, Germany) and mounted on Superfrost Plus glass slides (Thermo Fisher Scientific,
183 Waltham, MA, USA). Slides were then incubated at 56°C for 24 hours and stored at 4°C in
184 preparation for immunostaining.

185 **Immunohistochemistry and HPV detection**

186 Immunohistochemistry (IHC) was performed on TMA sections using a Ventana Benchmark
187 ULTRA Autostainer (Roche Tissue Diagnostics, Tucson, AZ, USA), according to the
188 manufacturer's instruction. CD4⁺ helper T cells, CD8⁺ cytotoxic T cells, CD68⁺ macrophages,
189 CD14⁺ monocytes, FoxP3⁺ regulatory T cells, and PD-L1⁺ cells were identified using the
190 antibodies summarized in Supplementary Table 1. The OptiView DAB IHC detection kit (Roche
191 Tissue Diagnostics) was used for detection of primary antibodies and visualization. The detailed
192 protocols for p16 and p53 IHC, HPV DNA PCR, and HPV mRNA *in situ* hybridization (ISH) are
193 described elsewhere (10, 22).

194

195 **Digital quantification and evaluation**

196 Immunostained TMAs were digitally scanned using a Hamamatsu NanoZoomer-XR whole slide
197 scanner (Hamamatsu Photonics, Hamamatsu City, Japan) at 40x magnification and analyzed using
198 the open-source software QuPath (version 0.4.0) (23). For digital quantification, epithelial and
199 stromal compartments of TMA cores were manually annotated using QuPath tools (Supplementary
200 Figure 1A). QuPath automated algorithms for setting vector stains and color-deconvolution were
201 then used to detect cell nuclei and immune markers based on adjusted hematoxylin and 3, 3'-
202 diaminobenzidine (DAB) thresholds (Supplementary Figure 1B-C). The hematoxylin and DAB
203 thresholds were maintained between slides of each marker to acquire homogenous results. Routine
204 calibration was performed together with a qualified pathologist (DEC). The number of positive
205 cells for each marker per mm² compartment was then calculated and the mean of all cores from
206 each individual patient sample was used for analysis. CD4⁺, CD8⁺, CD68⁺, CD14⁺, and FoxP3⁺
207 immune cells were dichotomized into high and low infiltration based on median positive cell

208 counts per mm² epithelial or stromal compartment for each respective marker (Supplementary
209 Figure 2). PD-L1 status was determined by using both the tumor proportion score method (TPS:
210 number of PD-L1+ tumor cells divided by the total number of tumor cells multiplied by 100) and
211 the combined positive score method (CPS: total number of PD-L1+ tumor cells and PD-L1+
212 stromal cells divided by the total number of tumor cells multiplied by 100) (24). Cases with a
213 discriminative cut-off value of TPS > 1 or CPS > 1 were considered PD-L1 positive.

214

215 **Statistical analysis**

216 All statistical analysis and data visualization was performed using IBM SPSS 25.0 (SPSS,
217 Chicago, IL) and R (version 4.3.0 or higher). Differences concerning infiltration of cells within
218 epithelial or stromal compartments were investigated using the Wilcoxon-Signed Rank Test. The
219 chi-squared test was used to explore associations between immune subsets and clinicopathological
220 features. The Mann-Whitney U test was used to study differences in the number of infiltrating cells
221 based on clinicopathological features. Correlations between different cell populations were
222 analyzed using the Spearman's rank correlation coefficient. Survival analysis was performed using
223 the R packages "survival" (v.3.5-7) and "survminer" (v.0.4.9) for Kaplan-Meier estimator, log-
224 rank test, and Cox regression models. p-values ≤ 0.05 were considered statistically significant.
225 Parameters that were significant in univariate analysis were further analyzed in multivariate
226 analysis. Progression free survival (PFS) was calculated as the time in months from the date of
227 termination of primary treatment to the date of recurrence or death. Disease specific survival (DSS)
228 was calculated as the time in months from date of primary treatment to the date of death from
229 disease. Patients alive at last contact or patients deceased from other causes were censored. The
230 "glmnet" package (v.4.1-8) was used for the least absolute shrinkage and selection operator

231 (LASSO) to determine immunoscores based on CD4+, CD8+, CD68+, CD14+, FoxP3+, and PD-
232 L1+ expression in epithelial and stromal compartments of tumors. Immunoscores were
233 dichotomized using the maximally selected rank statistics method in the survminer package or by
234 median values. Immunoscores and HPV mRNA ISH were used to construct logistic regression
235 models and nomograms using the “rms” (v.6.7-1) package and “dcurves” (v.0.4.0) was used for
236 decision curve analysis.

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254 Results

255 **Advanced stage VSCC and HPV-independent tumors displayed higher expression of PD-L1** 256 **and infiltration of CD68+ macrophages**

257 The number of infiltrating CD4+, CD8+, CD68+, CD14+, or FoxP3+ cells (Figure 1A) were higher
258 in the stroma of VSCC compared to the epithelium ($p < 0.05$), however no significant difference
259 was observed in the amount of PD-L1+ cells (Supplementary Figure 3A). CD68+ and CD14+
260 myeloid cells were the most prevalent immune cell subsets (Supplementary Table 2), and higher
261 infiltration of these cells in the epithelium was linked to clinicopathological features including
262 tumor size (Supplementary Table 3). Advanced tumors (FIGO stage III and IV) were more highly
263 populated with epithelial PD-L1+ and CD68+ cells (Figure 1B). Accordingly, tumors larger in size
264 ($> 4\text{cm}$) or with lymph node metastasis were found to have increased numbers of these subsets in
265 the epithelium. Larger tumors also demonstrated higher infiltration of CD14+ monocytes, in both
266 the epithelium and stroma (Supplementary Figure 3B-C). Within the advanced VSCC subgroup,
267 HPV-independent tumors (as determined by HPV mRNA ISH) demonstrated a higher number of
268 PD-L1+ cells in the stroma compared to HPV-associated counterparts ($p < 0.05$) (Figure 1C).
269 Moreover, HPV-independent tumors demonstrated higher stromal infiltration of both CD68+ and
270 CD14+ myeloid subsets in early stage VSCC (FIGO stage I and II). Further, the number of
271 epithelial CD68+ macrophages and stromal CD14+ monocytes were higher in tumors with *TP53*
272 mutations and no p16 expression (p53+/p16-) compared to the p53-/p16+ subtype (Supplementary
273 Figure 3D-E). Among T lymphocyte subsets, CD8+ cytotoxic T cells were the predominant group,
274 whereas the infiltration of CD4+ helper T cells was low, particularly in the epithelial compartments
275 (Supplementary Table 2). Apart from FoxP3+ regulatory T cells, which were associated with
276 disease specific survival ($p < 0.05$), no significant associations were found between infiltration of

277 T cell subsets and clinicopathological features (Supplementary Table 3). To explore the
278 correlations between PD-L1 and immune cell infiltration in the epithelial and stromal
279 compartments, the Spearman's rank correlation coefficient was utilized. The number of PD-L1+
280 cells was positively correlated with all immune subsets in both compartments ($p < 0.05$) (Figure
281 1D). The strongest correlation was identified between PD-L1+ cells and CD68+ macrophages in
282 the epithelium ($\rho = 0.80$) and stroma ($\rho = 0.71$) (Figure 1E-F) whereas CD4+, CD8+, CD14+, and
283 FoxP3+ infiltrates were moderately correlated with PD-L1+ ($\rho = 0.43-0.58$).

284

285 **Positive PD-L1 status independently predicted poor PFS**

286 Traditional prognostic factors for VSCC, including age and HPV status, were significantly linked
287 to survival in this cohort (Supplementary Table 4). The analysis was expanded to assess the
288 prognostic impact of stratifying patients by immune cell infiltration and PD-L1 status. Kaplan-
289 Meier analysis revealed positive PD-L1 status (TPS > 1) or high stromal infiltration of CD14+
290 monocytes to be associated with poor PFS (log rank test: $p = 0.002$ and $p = 0.015$, respectively)
291 (Figure 2A). This was also the case for high infiltration of CD68+ macrophages in stromal or
292 epithelial compartments (log rank test: $p = 0.019$ and $p = 0.042$ respectively) (Figure 2A and
293 Supplementary Figure 4A-B). Furthermore, high infiltration of either CD68+ macrophages or
294 CD14+ monocytes in the stroma predicted poor DSS (log rank test: $p = 0.011$ and $p = 0.027$
295 respectively). In contrast, high epithelial infiltration of FoxP3+ T cells was associated with more
296 favorable DSS outcomes (log rank test: $p = 0.036$) (Figure 2B). Results from the univariate Cox
297 analysis aligned with these findings however, after adjusting for age and HPV status in the
298 multivariate Cox analysis, only PD-L1 status (TPS > 1) remained an independent prognostic
299 indicator for PFS (HR = 1.80, $p = 0.041$). In contrast PD-L1 status as determined by CPS > 1 , was

300 not significantly associated with PFS (Table 1). None of the investigated markers demonstrated
301 independent prognostic value for DSS after adjusting for confounders. In this cohort, 58/117
302 primary tumors (49.6%), 21/29 recurrences (72.4%), and 25/36 metastatic lesions (69.4%) were
303 PD-L1 positive (TPS > 1). Moreover, variations in PD-L1 status were evident between primary
304 tumors and their respective recurrent or metastatic counterparts (Figure 2C-D). Within the cohort
305 of PD-L1 negative primary tumors, eight of the matched recurrences (61.5%) and four of the
306 matched metastases (30.8%) were PD-L1 positive respectively (Figure 2E-F). Consistent with PD-
307 L1+ infiltration patterns, positive PD-L1 status was associated with HPV-independent VSCC and
308 the p53+/p16- subtype (Table 2).

309

310 **Construction of immunoscore models with independent prognostic value for PFS and DSS**

311 To further evaluate prognostic epithelial and stromal immune features and establish a combined
312 immunoscore, the LASSO Cox regression model was used in which tuning parameter (λ) values
313 were selected by 10-fold cross-validation (via minimum criteria) (Figure 3A, Supplementary
314 Figure 5A). This identified four non-zero coefficients based on PFS and five non-zero coefficients
315 based on DSS (Figure 3B, Supplementary Figure 5B). Immunoscores were subsequently
316 calculated using these coefficients: $\text{immunoscore}^{\text{PFS}} = (1.8609 \times \text{number of epithelial PD-L1+}$
317 $\text{cells/mm}^2) + (-4.5255 \times \text{number of epithelial CD8+ cells/mm}^2) + (2.1746 \times \text{number of epithelial}$
318 $\text{FoxP3+ cells/mm}^2) + (0.1497 \times \text{number of stromal CD14+cells/mm}^2) \times 10^{-4}$ and $\text{immunoscore}^{\text{DSS}}$
319 $= (0.2744 \times \text{number of stromal PD-L1+ cells/mm}^2) + (-0.1481 \times \text{number of epithelial CD8+}$
320 $\text{cells/mm}^2) + (-3.160 \times \text{number of epithelial FoxP3+ cells/mm}^2) + (-0.0143 \times \text{number of epithelial}$
321 $\text{CD14+cells/mm}^2) + (0.1436 \times \text{number of stromal CD14+cells/mm}^2) \times 10^{-3}$). Next, the association
322 between immunoscores and survival outcomes was investigated. In multivariate Cox analysis,
323 $\text{immunoscore}^{\text{PFS}}$ and $\text{immunoscore}^{\text{DSS}}$ were independent prognosticators of PFS (HR = 5.09, p =

324 0.001) and DSS (HR = 5.98, $p = 0.007$) respectively after adjusting for confounders (Figure 3C-
325 D). When dichotomizing immunoscores using the maximally selected rank statistics method
326 Kaplan Meier analysis showed that a high immunoscore^{PFS} was associated with poor PFS (log rank
327 test: $p < 0.001$) and a high immunoscore^{DSS} predicted poor DSS (log rank test: $p < 0.001$) (Figure
328 3E). The VSCC cohort was then stratified by HPV mRNA ISH status to investigate the prognostic
329 contribution of immunoscores within the HPV-independent subgroup. This analysis revealed that
330 a low immunoscore^{PFS} and a low immunoscore^{DSS} significantly predicted favorable PFS (log rank
331 test: $p < 0.001$) and DSS (log rank test: $p < 0.001$), respectively in HPV-independent tumors
332 (Figure 3F). In contrast to the maximally selected rank statistics method, only immunoscore^{DSS}
333 was significantly associated with DSS in the entire cohort (log rank test: $p = 0.002$) when
334 immunoscores were dichotomized by median values (Figure 3G).

335

336 **Integration of immunoscores with HPV status and validation of the prognostic models**

337 Drawing upon the prognostic implications of immunoscores and HPV status, we amalgamated
338 these variables to formulate nomograms termed as immunoscore-HPV (IS-HPV) index^{PFS} and IS-
339 HPV index^{DSS} (Figure 4A). Using the nomograms, the probability of an outcome can be predicted
340 by calculating a total score based on the points contributed by immunoscore and HPV status
341 predictors. A bootstrap resampling approach was employed to generate 1,000 iterations for internal
342 validation of the immunoscore and IS-HPV index models. Calibration plots indicated satisfactory
343 agreement between observed outcomes and predicted outcomes from the nomograms. The IS-HPV
344 index^{PFS} and IS-HPV index^{DSS} concordance (c)-index were 0.752 (corrected c-index: 0.750) and
345 0.760 (corrected c-index: 0.752) for PFS and DSS, respectively (Figure 4B). Comparatively, the
346 corrected c-index for HPV status-based models alone was 0.666 for PFS and 0.631 for DSS. For

347 immunoscore^{PFS} and immunoscore^{DSS} based models the corrected c-index were 0.667 and 0.715
348 for PFS and DSS respectively. To further assess the efficacy of the nomograms an IS-HPV index
349 score was computed for all the patients in the cohort based on coefficients derived from logistic
350 regression models used to construct the nomograms: IS-HPV index^{PFS} score = (1.558 x
351 immunoscore) + (-1.931 x HPV status) and IS-HPV index^{DSS} score = (2.152 x immunoscore) + (-
352 2.066 x HPV status). The IS-HPV index scores were then dichotomized based on the maximally
353 selected rank statistics method to select a cutoff (-0.430 for IS-HPV index^{PFS} and -0.028 for IS-
354 HPV index^{DSS}) for Kaplan-Meier analysis. High IS-HPV index^{PFS} and IS-HPV index^{DSS} scores
355 were associated with poor PFS (log rank test: p < 0.001) and DSS (log rank test: p < 0.001)
356 respectively (Figure 4C) and an improved discriminatory ability was observed for DSS when
357 comparing the IS-HPV index^{DSS} to HPV status alone (Supplementary Figure 6). Furthermore,
358 decision curve analysis demonstrated a clear net benefit from using the IS-HPV index^{PFS}
359 nomogram when the threshold probability exceeded 0.15 PFS, and consistently across all threshold
360 probabilities for DSS. At clinically relevant threshold probabilities for DSS, the integrated IS-HPV
361 index^{DSS} model surpassed the performance of the immunoscore and HPV status models
362 individually (Figure 4D).

363

364

365

366

367

368

369

370

371 Discussion

372 It is becoming increasingly evident that the efficacy of immunotherapeutic modalities in cancer is
373 affected by the ability to establish an enduring immune response. Indeed, the local immune
374 infiltrate undergoes dynamic changes following treatment and may be indicative of prognosis in
375 cancer (12). The association between *in-situ* infiltration of immune cell subsets and survival in
376 VSCC remains unclear and the search for novel biomarkers continues. Here, we developed the
377 first immunoscore model for VSCC by interrogating PD-L1 expression and immune cell
378 infiltration patterns in the epithelium and stroma of tumors. Our analysis revealed that
379 immunoscores independently predict survival in VSCC providing superior prognostication
380 compared to immunological features assessed alone. Furthermore, integrating immunoscores with
381 HPV status and establishing an IS-HPV index improved the prognostic impact of the models.

382
383 VSCC manifests through two distinct molecular pathways: HPV-independent and HPV-associated
384 disease (25). Studies have shown that HPV-independent tumors are associated with poorer survival
385 (10, 11, 26) and novel biomarkers are needed to categorize these cases. Immunoscores are
386 prognostic tools focused on tumor immune interactions, that may contribute additional clinical
387 value to traditional staging systems (27). Even though combined risk factor models have been
388 presented for VSCC (28, 29), immunoscores have yet to be explored. In this study low
389 immunoscores corresponded with improved PFS and DSS respectively in HPV-independent
390 tumors suggesting that clinical use of immunoscores could improve risk stratification in VSCC.
391 Moreover, immunoscores were independent predictors of survival in the entire VSCC cohort,
392 corroborating findings from other cancer types (30, 31), although the immunological features used
393 to determine the models differed. Previously, immunoscores were established based on infiltration

394 of T cells (19, 27, 32) however in this study myeloid subsets were also included to more accurately
395 reflect the immune landscape. Besides the number of infiltrating immune cells, studies have also
396 shown that the spatiotemporal dynamics influence disease progression (33). We therefore spatially
397 resolved immunological features and investigated the epithelial or stromal specific contribution
398 instead of only focusing on the density of cells (34). To accomplish this, IHC and digital
399 quantification were used to determine immunoscores. The immunoscores were then integrated
400 with HPV status to form easy-to-use nomograms. At clinically relevant threshold probabilities for
401 DSS, our data indicates that using the nomogram may offer additional clinical benefit to VSCC
402 patients compared to HPV status or immunoscore based models alone. Similarly, He et al
403 demonstrated that combining immunoscores with clinicopathological features improved the
404 impact of the models in non-small cell lung carcinoma (NSCLC) (35). Taken together, our findings
405 suggest that the IS-HPV index model could be a rapid and cost-effective diagnostic test to improve
406 risk stratification in VSCC and may enable selection of patients who are likely to benefit from less
407 aggressive treatment regimens. Furthermore, the immunoscores may demonstrate predictive value
408 for immunotherapy, as recently reported for NSCLC (36), however we were unable to assess this
409 in our cohort as patients had not received immunotherapy.

410

411 We also assessed the immunological features used to determine immunoscores individually. PD-
412 L1 is pivotal in cancer immunoediting and the expression level impacts patient survival outcomes
413 in many cancer types (37). Consistent with Hecking et al, our data indicates that positive PD-L1
414 status (TPS > 1) is an independent prognostic factor associated with poor survival, HPV-
415 independent disease (17), and the p53+/p16- subtype. Other studies found no association between
416 epithelial PD-L1 expression and survival (38, 39). The discrepancies may stem from variations in

417 sample size or methodologies and thresholds used to define PD-L1 status. Considering the rarity
418 of this disease, a relatively large cohort was recruited in this study and PD-L1 expression was
419 determined by IHC and digital image analysis instead of manual scoring or genomic profiling. PD-
420 L1 status was determined by TPS > 1 contrasting other studies where higher thresholds were used
421 (18, 39, 40). Future work is needed to harmonize scoring and cut-offs to evaluate the prognostic
422 importance of PD-L1 in VSCC. Notably, PD-L1 status was discordant when comparing primary
423 tumors to corresponding recurrent or metastatic lesions, aligning with previous reports (38),
424 indicating it may be important to retest this marker in metastatic or recurrent VSCC.

425
426 Our data revealed a strong correlation between the number of PD-L1+ cells and infiltration of
427 CD68+ macrophages in both the epithelium and stroma of VSCC. Studies have suggested that
428 tumor associated macrophages (TAMs) are the predominant immune cells that express PD-L1
429 along with cancer cells in NSCLC and breast cancer (41, 42). The strong correlation we observed
430 may therefore be due to the presence of TAMs expressing CD68+ and PD-L1+ surface markers.
431 Additionally, high stromal infiltration of CD68+ macrophages was linked to HPV-independent
432 tumors and poorer survival outcomes. Condic et al. reported that CD163+ TAMs were an
433 unfavorable prognostic variable in VSCC (43). While CD68+ serves as a universal marker for
434 macrophages, CD163+ is predominantly expressed by the M2-polarized subtype. Similar to
435 CD68+ macrophages, high stromal CD14+ monocyte infiltration was linked to poor survival and
436 HPV-independent pathogenesis. Van Esch et al showed no significant association between stromal
437 CD14+ infiltration and survival in vulvar epithelial neoplasia lesions, however HPV-independent
438 VSCC cases which constitute most of our cohort, were not assessed in their study (44). In contrast,
439 Abdulrahman et al reported that a strong epithelial CD14+ infiltration was associated with

440 improved survival (45). Importantly, these cells were negative for other myeloid markers while
441 our study consisted of a mixed population of CD14+ positive cells. Future work should aim to
442 decipher the macrophage and monocyte subtypes in our cohort.

443

444 Lymphocytes, particularly CD8+ T cells, are essential effectors in the adaptive immune response
445 against tumors (46). In accordance with other studies, we found no correlation between epithelial
446 CD8+ T cell infiltration and survival in VSCC (47). Conversely, Kortekaas, et al. reported that
447 CD3+CD8+Foxp3- T cell infiltration in the epithelial compartments was correlated with favorable
448 survival (15). An earlier study reported no association between this T cell subset and survival,
449 irrespective of dichotomization using median values or ROC analysis (16) highlighting the need
450 for further research. Inconsistent with our results, the number of CD3+CD8+FoxP3- and
451 CD3+CD8-FoxP3+ T cells were significantly different when comparing HPV-independent and
452 HPV-associated disease in the abovementioned study. The discrepancies may be due to differences
453 in the investigated immune cell subtypes. Although epithelial infiltration of FoxP3+ T cells was
454 associated with improved DSS, independent prognostic value was not observed in this study
455 conflicting with another report (48). Here, the prognostic impact of FoxP3+ was adjusted for HPV
456 mRNA ISH instead of p16 IHC as a surrogate marker for HPV. Our group recently demonstrated
457 differences concerning HPV mRNA ISH and p16 IHC for prediction of survival in VSCC (10).

458

459 This study has limitations such as the retrospective study design and the recruitment of all
460 participants from one single center. To mitigate the limitations, thorough internal validation was
461 conducted. However, multicenter prospective studies are necessary to further confirm the
462 generalizability of our findings. In this study PD-L1 expression and immune cell infiltration were

463 investigated using IHC and digital image analysis based on established algorithms. A key
464 advantage of this approach is the acquisition of data through unbiased measurements. However,
465 the method faces challenges, including difficulties applying automated workflows to produce
466 accurate results due to biomarker heterogeneity and divergences in tissue samples. Routine
467 calibration with a pathologist was performed to ensure analysis validity. Furthermore, data
468 acquired from TMA cores may not be biologically representative due to intra- tumor heterogeneity.
469 We attempted to mitigate the impact of this by averaging two or three cores per case for
470 downstream analysis. Additionally, our data demonstrated that the method of dichotomization may
471 influence analysis outcomes. Future studies are therefore required to determine the optimal
472 approach for dichotomizing biomarkers to binary variables (49).

473

474 In summary, this study provides a comprehensive analysis of PD-L1 expression and immune cell
475 infiltration in epithelial and stromal compartments of VSCC. For the first time, we introduce a
476 VSCC immunoscore designed to enhance disease risk stratification. By integrating this
477 immunoscore with HPV status, determined via HPV mRNA ISH, we established an immunoscore-
478 HPV index for prediction of PFS and DSS in VSCC. Additional research is necessary to confirm
479 the accuracy and clinical utility of the immunoscore-HPV index models.

480

481

482

483

484

485

486 **Abbreviations:**

487 C-INDEX: concordance-index

488 DSS: disease specific survival

489 FFPE: formalin-fixed paraffin embedded

490 FIGO: the International Federation of Gynecology and Obstetrics

491 HPV: human papilloma virus

492 HUS: Haukeland University Hospital

493 IHC: immunohistochemistry

494 ISH: in situ hybridization

495 IS-HPV: immunoscore-human papilloma virus index

496 LASSO: least absolute shrinkage and selection operator

497 PCR: polymerase chain reaction

498 PD-1: programmed cell death protein-1

499 PD-L1: programmed death ligand protein-1

500 PFS: progression free survival

501 REK: Regional Committee for Medical and Health Research Ethics

502 TIME: tumor immune microenvironment

503 TMA: tissue microarray

504 VSCC: vulva squamous cell carcinoma

505

506

507

508 **Declarations**

509 **Ethics approval and consent to participate**

510 This study was approved by the Regional Committee for Medical and Health Research Ethics
511 Norway (REK Nos: 2017/279 and 2014/1907). Written consent was obtained from all participants
512 included in this study.

513

514 **Consent for publication**

515 Not applicable

516

517 **Availability of data and materials**

518 Data associated with the findings of this study are included in the article or in the uploaded
519 supplementary files and are available from the corresponding author upon reasonable request.

520

521 **Competing interests**

522 None

523

524 **Funding**

525 This study was supported by The Research Council of Norway through its Centers of Excellence
526 funding scheme (DEC, Grant No. 22325 to Center of Excellency for Cancer Biomarkers CCBIO),
527 The Western Norway Regional Health Authority (DEC, Helse Vest Grant Nos 912260/2019 and
528 F-13105/2024), and the Norwegian Women's Public Health Association (Grant no. 40021).

529

530 **Authors' contributions**

531 Conceptualization, RE, DEC, LB and HND; data curation, RE, LB and HND; formal analysis,
532 RE and HND; funding acquisition, HND, LB and DEC; investigation, RE, IHH, MF, IBMK,
533 LCVT and HND; methodology, RE, IHH, MF and HND; project administration, DEC, LB and
534 HND; supervision, DEC, LB and HND; validation, RE and HND; visualization, RE, IBMK,
535 LVCT; writing—original draft, RE and HND; writing—review & editing, RE, HND, DEC and
536 LB. All authors have read and agreed to the published version of the manuscript.

537

538 **Acknowledgements**

539 We would like to thank all the patients who participated in this study.

540

541

542

543

544

545

546

547

548

549

550

551 References

- 552 1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global
553 cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36
554 cancers in 185 countries. *CA Cancer J Clin.* 2024;74(3):229-63.
- 555 2. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. *CA Cancer J Clin.*
556 2024;74(1):12-49.
- 557 3. Meltzer-Gunnes CJ, Lie AK, Jonassen CGM, Rangberg A, Nystrand CF, Smastuen MC,
558 et al. Time trends in human papillomavirus prevalence and genotype distribution in vulvar
559 carcinoma in Norway. *Acta Obstet Gynecol Scand.* 2024;103(1):153-64.
- 560 4. Zach D, Avall-Lundqvist E, Falconer H, Hellman K, Johansson H, Floter Radestad A.
561 Patterns of recurrence and survival in vulvar cancer: A nationwide population-based study.
562 *Gynecol Oncol.* 2021;161(3):748-54.
- 563 5. Nooij LS, Brand FA, Gaarenstroom KN, Creutzberg CL, de Hullu JA, van Poelgeest MI.
564 Risk factors and treatment for recurrent vulvar squamous cell carcinoma. *Crit Rev Oncol*
565 *Hematol.* 2016;106:1-13.
- 566 6. Schnack TH, Froeding LP, Kristensen E, Niemann I, Ortoft G, Hogdall E, et al.
567 Preoperative predictors of inguinal lymph node metastases in vulvar cancer - A nationwide
568 study. *Gynecol Oncol.* 2022;165(3):420-7.
- 569 7. Soderini A, Aragona A, Reed N. Advanced Vulvar Cancers: What are the Best Options
570 for Treatment? *Curr Oncol Rep.* 2016;18(10):64.
- 571 8. Weberpals JI, Lo B, Duciaume MM, Spaans JN, Clancy AA, Dimitroulakos J, et al.
572 Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct

- 573 Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3. *Clin Cancer Res.*
574 2017;23(15):4501-10.
- 575 9. Hinten F, Molijn A, Eckhardt L, Massuger L, Quint W, Bult P, et al. Vulvar cancer: Two
576 pathways with different localization and prognosis. *Gynecol Oncol.* 2018;149(2):310-7.
- 577 10. Dongre HN, Elnour R, Tornaas S, Fromreide S, Thomsen LCV, Kolseth IBM, et al. TP53
578 mutation and human papilloma virus status as independent prognostic factors in a Norwegian
579 cohort of vulva squamous cell carcinoma. *Acta Obstet Gynecol Scand.* 2024;103(1):165-75.
- 580 11. Kortekaas KE, Bastiaannet E, van Doorn HC, de Vos van Steenwijk PJ, Ewing-Graham
581 PC, Creutzberg CL, et al. Vulvar cancer subclassification by HPV and p53 status results in three
582 clinically distinct subtypes. *Gynecol Oncol.* 2020;159(3):649-56.
- 583 12. Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer
584 prognosis and therapeutic efficacy. *Nat Rev Cancer.* 2020;20(11):662-80.
- 585 13. Santoro A, Angelico G, Inzani F, Arciuolo D, d'Amati A, Addante F, et al. The emerging
586 and challenging role of PD-L1 in patients with gynecological cancers: An updating review with
587 clinico-pathological considerations. *Gynecol Oncol.* 2024;184:57-66.
- 588 14. Schwab R, Schiestl LJ, Cascant Ortolano L, Klecker PH, Schmidt MW, Almstedt K, et
589 al. Efficacy of pembrolizumab in advanced cancer of the vulva: a systematic review and single-
590 arm meta-analysis. *Front Oncol.* 2024;14:1352975.
- 591 15. Kortekaas KE, Santegoets SJ, Tas L, Ehsan I, Charoentong P, van Doorn HC, et al.
592 Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune
593 signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy. *J Immunother*
594 *Cancer.* 2021;9(10).







- 595 16. Kortekaas KE, Santegoets SJ, Abdulrahman Z, van Ham VJ, van der Tol M, Ehsan I, et
596 al. High numbers of activated helper T cells are associated with better clinical outcome in early
597 stage vulvar cancer, irrespective of HPV or p53 status. *J Immunother Cancer*. 2019;7(1):236.
- 598 17. Hecking T, Thiesler T, Schiller C, Lunkenheimer JM, Ayub TH, Rohr A, et al. Tumoral
599 PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral
600 etiology. *Oncotarget*. 2017;8(54):92890-903.
- 601 18. Sznurkowski JJ, Zawrocki A, Sznurkowska K, Peksa R, Biernat W. PD-L1 expression on
602 immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients.
603 *Oncotarget*. 2017;8(52):89903-12.
- 604 19. Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, et al. International
605 validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and
606 accuracy study. *Lancet*. 2018;391(10135):2128-39.
- 607 20. Pages F, Andre T, Taieb J, Vernerey D, Henriques J, Borg C, et al. Prognostic and
608 predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in
609 the prospective IDEA France PRODIGE-GERCOR cohort study. *Ann Oncol*. 2020;31(7):921-9.
- 610 21. Argiles G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised
611 colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann*
612 *Oncol*. 2020;31(10):1291-305.
- 613 22. Haave H, Gulati S, Brekke J, Lybak S, Vintermyr OK, Aarstad HJ. Tumor stromal
614 desmoplasia and inflammatory response uniquely predict survival with and without stratification
615 for HPV tumor infection in OPSCC patients. *Acta Otolaryngol*. 2018;138(11):1035-42.
- 616 23. Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, et al.
617 QuPath: Open source software for digital pathology image analysis. *Sci Rep*. 2017;7(1):16878.

- 618 24. Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis
619 of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. *J*
620 *Immunother Cancer*. 2019;7(1):278.
- 621 25. Clancy AA, Spaans JN, Weberpals JI. The forgotten woman's cancer: vulvar squamous
622 cell carcinoma (VSCC) and a targeted approach to therapy. *Ann Oncol*. 2016;27(9):1696-705.
- 623 26. Allo G, Yap ML, Cuartero J, Milosevic M, Ferguson S, Mackay H, et al. HPV-
624 independent Vulvar Squamous Cell Carcinoma is Associated With Significantly Worse
625 Prognosis Compared With HPV-associated Tumors. *Int J Gynecol Pathol*. 2020;39(4):391-9.
- 626 27. Angell HK, Bruni D, Barrett JC, Herbst R, Galon J. The Immunoscore: Colon Cancer and
627 Beyond. *Clin Cancer Res*. 2020;26(2):332-9.
- 628 28. Zhang T, Zhu Y, Luo J, Li J, Niu S, Chen H, et al. An integrated model for prognosis in
629 vulvar squamous cell carcinoma. *BMC Cancer*. 2023;23(1):534.
- 630 29. Zhao Z, Zhen S, Liu N, Ding D, Zhang D, Kong J. Survival nomograms for vulvar
631 squamous cell carcinoma based on the SEER database and a Chinese external validation cohort.
632 *Int J Gynaecol Obstet*. 2024;165(3):1130-43.
- 633 30. Ghiringhelli F, Bibeau F, Greillier L, Fumet JD, Ilie A, Monville F, et al. Immunoscore
634 immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive
635 of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer. *EBioMedicine*.
636 2023;92:104633.
- 637 31. Mezheyski A, Backman M, Mattsson J, Martin-Bernabe A, Larsson C, Hrynchyk I, et
638 al. An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has
639 major prognostic impact and predicts immunotherapy response in solid cancers. *EBioMedicine*.
640 2023;88:104452.







- 641 32. Han B, Yim J, Lim S, Na S, Lee C, Kim TM, et al. Prognostic Impact of the
642 Immunoscore Based on Whole-Slide Image Analysis of CD3+ Tumor-Infiltrating Lymphocytes
643 in Diffuse Large B-Cell Lymphoma. *Mod Pathol.* 2023;36(9):100224.
- 644 33. Mezheyeuski A, Bergsland CH, Backman M, Djureinovic D, Sjoblom T, Bruun J, et al.
645 Multispectral imaging for quantitative and compartment-specific immune infiltrates reveals
646 distinct immune profiles that classify lung cancer patients. *J Pathol.* 2018;244(4):421-31.
- 647 34. Nie RC, Yuan SQ, Wang Y, Chen YB, Cai YY, Chen S, et al. Robust immunoscore
648 model to predict the response to anti-PD1 therapy in melanoma. *Aging (Albany NY).*
649 2019;11(23):11576-90.
- 650 35. He L, Huang Y, Chen X, Huang X, Wang H, Zhang Y, et al. Development and
651 Validation of an Immune-Based Prognostic Risk Score for Patients With Resected Non-Small
652 Cell Lung Cancer. *Front Immunol.* 2022;13:835630.
- 653 36. Hijazi A, Antoniotti C, Cremolini C, Galon J. Light on life: immunoscore immune-
654 checkpoint, a predictor of immunotherapy response. *Oncoimmunology.* 2023;12(1):2243169.
- 655 37. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in
656 cancer suppression and promotion. *Science.* 2011;331(6024):1565-70.
- 657 38. Lerias S, Esteves S, Silva F, Cunha M, Cochicho D, Martins L, et al. CD274 (PD-L1),
658 CDKN2A (p16), TP53, and EGFR immunohistochemical profile in primary, recurrent and
659 metastatic vulvar cancer. *Mod Pathol.* 2020;33(5):893-904.
- 660 39. Thangarajah F, Morgenstern B, Pahmeyer C, Schiffmann LM, Puppe J, Mallmann P, et
661 al. Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva. *J Cancer*
662 *Res Clin Oncol.* 2019;145(6):1651-60.

- 663 40. Czogalla B, Pham D, Trillsch F, Rottmann M, Gallwas J, Burges A, et al. PD-L1
664 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva. *J*
665 *Cancer Res Clin Oncol*. 2020;146(3):569-77.
- 666 41. Liu Y, Zugazagoitia J, Ahmed FS, Henick BS, Gettinger SN, Herbst RS, et al. Immune
667 Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway
668 Blockade Therapy. *Clin Cancer Res*. 2020;26(4):970-7.
- 669 42. Wang L, Guo W, Guo Z, Yu J, Tan J, Simons DL, et al. PD-L1-expressing tumor-
670 associated macrophages are immunostimulatory and associate with good clinical outcome in
671 human breast cancer. *Cell Rep Med*. 2024;5(2):101420.
- 672 43. Condic M, Rohr A, Riemann S, Staerk C, Ayub TH, Doeser A, et al. Immune Profiling of
673 Vulvar Squamous Cell Cancer Discovers a Macrophage-rich Subtype Associated with Poor
674 Prognosis. *Cancer Res Commun*. 2024;4(3):861-75.
- 675 44. van Esch EM, van Poelgeest MI, Trimbos JB, Fleuren GJ, Jordanova ES, van der Burg
676 SH. Intraepithelial macrophage infiltration is related to a high number of regulatory T cells and
677 promotes a progressive course of HPV-induced vulvar neoplasia. *Int J Cancer*. 2015;136(4):E85-
678 94.
- 679 45. Abdulrahman Z, Kortekaas KE, Welters MJP, van Poelgeest MIE, van der Burg SH.
680 Monocyte infiltration is an independent positive prognostic biomarker in vulvar squamous cell
681 carcinoma. *Cancer Immunol Immunother*. 2024;73(9):166.
- 682 46. Raskov H, Orhan A, Christensen JP, Gogenur I. Cytotoxic CD8(+) T cells in cancer and
683 cancer immunotherapy. *Br J Cancer*. 2021;124(2):359-67.


- 684 47. Burandt E, Blessin NC, Rolschewski AC, Lutz F, Mandelkow T, Yang C, et al. T-Cell
685 Density at the Invasive Margin and Immune Phenotypes Predict Outcome in Vulvar Squamous
686 Cell Cancer. *Cancers (Basel)*. 2022;14(17).
- 687 48. Arik D, Benli T, Telli E. Number of FoxP3+ regulatory T-cells are associated with
688 recurrence in vulvar squamous cell carcinoma. *J Gynecol Oncol*. 2023;34(2):e16.
- 689 49. Prince Nelson SL, Ramakrishnan V, Nietert PJ, Kamen DL, Ramos PS, Wolf BJ. An
690 evaluation of common methods for dichotomization of continuous variables to discriminate
691 disease status. *Commun Stat Theory Methods*. 2017;46(21):10823-34.
- 692




694 **Figure 1: PD-L1 expression and immune cell infiltration in VSCC.** (A) Representative
695 immunohistochemical staining of CD4+, CD8+, CD68+, CD14+, FoxP3+, and PD-L1+ cells.
696 Scale bar = 50 μm . (B) Box plots depicting differences in the number of cells per mm^2 based on
697 FIGO stage. (C) Box plots depicting differences in the number of cells per mm^2 based on HPV
698 status, as determined by HPV mRNA ISH, within the advanced VSCC subgroup (FIGO stage
699 III/IV). p-values ≤ 0.05 were considered statistically significant. The box shows the interquartile
700 range, and medians are highlighted with a black line. Individual cases are represented by black
701 dots. (D) Matrix showing correlations between immune subsets. Spearman's rank correlation
702 coefficients (ρ) are provided in each box of the matrix. Larger circles with darker shades of blue
703 demonstrate stronger positive correlations. Correlations that were not statistically significant ($p >$
704 0.05) are shown as blank. Scatterplots with fitted regression lines and 95% confidence interval
705 showing correlations between PD-L1+ and CD68+ cells in (E) epithelial and (F) stromal
706 compartments.



708 **Figure 2: Prognostic value of PD-L1 status and immune cell infiltration.** Kaplan-Meier curves
709 demonstrating influence of PD-L1 status and stromal CD68+ or CD14+ infiltration on (A)
710 progression free- and (B) disease specific survival. p-values < 0.05 were considered statistically
711 significant based on the log rank test. Representative immunohistochemical staining of cases with
712 discordant PD-L1 expression in primary tumors and corresponding (C) recurrences or (D)
713 metastatic lesions. Scale bar = 50 μ m. PD-L1 status patterns in primary tumors and matched (E)
714 recurrences or (F) metastatic lesions.



716 **Figure 3: Determining immunoscores based on the LASSO cox regression model.** (A) Immune
717 feature selection for prediction of PFS by applying 10-fold cross-validation and training a LASSO
718 regression model. The dotted vertical lines indicate selected λ values using minimum criteria. (B)
719 Regression coefficient profiles of epithelial and stromal CD4+, CD8+, CD68+, CD14+, FoxP3+,
720 and PD-L1+ subsets in the LASSO regression model. Forest plots demonstrating the association
721 of immunoscores and clinicopathological features on (D) PFS and (E) DSS. Hazard ratios (HR)
722 with 95% confidence interval (C.I.) and p-values are shown. Kaplan-Meier curves showing the
723 influence of immunoscores, dichotomized by the maximally selected rank statistics (maxstat*)
724 method, on PFS and DSS for the (E) entire cohort and (F) HPV-independent subgroup. (G) Kaplan-
725 Meier curves showing the influence of immunoscores, dichotomized by median values, on PFS
726 and DSS for the entire cohort



727

728 **Figure 4: Construction of immunoscore-HPV index nomograms.** (A) Immunoscore-HPV (IS-

729 HPV) index nomograms for PFS and DSS. (B) Calibration plots demonstrating the agreement

730 between nomogram predicted outcomes and actual survival outcomes. Concordance index (c-

731 index) and corrected (corr) c-index values are provided. IS-HPV index scores were calculated for

732 the entire VSCC cohort using coefficients from the logistic regression model and dichotomized

733 based on the maximally selected rank statistics method. (C) Kaplan-Meier curves showing the

734 influence of IS-HPV index on PFS and DSS. (D) Decision curve analysis for the nomograms for
735 PFS and DSS.

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757 **Table 1:** Influence of PD-L1 status and immune cell infiltration on progression free- and disease
 758 specific survival. In the multivariate analysis PFS was adjusted for age and HPV mRNA ISH. DSS
 759 was adjusted for age, tumor size, and HPV mRNA ISH.

Progression free survival		Univariate analysis			Multivariate analysis		
		HR	(95% CI)	p-value	HR	(95% CI)	p-value
PD-L1	TPS ≥ 1	2.349	1.342-4.112	0.003	1.802	1.024-3.170	0.041
PD-L1	CPS ≥ 1	2.000	0.975-4.106	0.059	-	-	-
CD4	High epithelial Infiltration	0.969	0.565-1.662	0.908	-	-	-
	High stromal Infiltration	0.874	0.509-1.500	0.625	-	-	-
CD8	High epithelial Infiltration	0.831	0.483-1.429	0.503	-	-	-
	High stromal Infiltration	0.994	0.580-1.705	0.983	-	-	-
CD68	High epithelial Infiltration	1.754	1.014-3.031	0.044	1.532	0.880-2.667	0.132
	High stromal Infiltration	1.920	1.107-3.330	0.020	1.497	0.861-2.604	0.153
CD14	High epithelial Infiltration	1.488	0.864-2.561	0.151	-	-	-
	High stromal Infiltration	1.957	1.131-3.387	0.016	1.578	0.893-2.789	0.116
FOXP3	High epithelial Infiltration	0.808	0.471-1.386	0.439	-	-	-
	High stromal Infiltration	0.983	0.574-1.685	0.951	-	-	-
Disease specific survival		Univariate analysis			Multivariate analysis		
		HR	(95% CI)	p-value	HR	(95% CI)	p-value

PD-L1	TPS ≥ 1	1.878	0.816-4.323	0.139	-	-	-
PD-L1	CPS ≥ 1	1.479	0.546-4.001	0.441	-	-	-
CD4	High epithelial Infiltration	0.782	0.342-1.790	0.561	-	-	-
CD4	High stromal Infiltration	0.765	0.335-1.745	0.524	-	-	-
CD8	High epithelial Infiltration	0.651	0.281-1.506	0.316	-	-	-
	High stromal Infiltration	1.126	0.496-2.555	0.776	-	-	-
CD68	High epithelial Infiltration	1.541	0.673-3.529	0.307	-	-	-
	High stromal Infiltration	2.995	1.241-7.225	0.015	1.944	0.796-4.751	0.145
CD14	High epithelial Infiltration	1.149	0.505-2.615	0.741	-	-	-
	High stromal Infiltration	2.566	1.083-6.081	0.032	1.526	0.597-3.899	0.378
FOXP3	High epithelial Infiltration	0.397	0.163-0.966	0.042	0.533	0.215-1.317	0.173
	High stromal Infiltration	0.868	0.383-1.969	0.736	-	-	-

760

761

762 **Table 2:** Relationship between PD-L1 status, as determined by TPS > 1, and clinicopathological
763 features.

Parameters	PD-L1 Status			χ^2 (p-value)
	n=117	Positive (%)	Negative (%)	
Age				
< 71 years	57 (48.7%)	24 (20.5%)	33 (28.2%)	3.079
≥ 71 years	60 (51.3%)	35 (29.9%)	25 (21.4%)	(0.079)
BMI				
Normal	31 (26.5%)	13 (11.1%)	18 (15.4%)	1.462
Overweight/obese	54 (46.2%)	30 (25.6%)	24 (20.5%)	(0.227)
Unknown	32 (27.3%)	15 (12.8%)	17 (14.5%)	
FIGO stage				
Stage I & II	78 (66.7%)	35 (29.9%)	43 (36.8%)	2.889
Stage III & IV	39 (33.3%)	24 (20.5%)	15 (12.8%)	(0.089)
Tumor size				
≤ 4cm	81 (69.2%)	37 (31.6%)	44 (37.6%)	2.374
> 4cm	36 (30.8%)	22 (18.8%)	14 (12.0%)	(0.123)
Lymph node metastasis				
No	79 (67.5%)	35 (29.9%)	44 (37.6%)	3.649
Yes	38 (32.5%)	24 (20.5%)	14 (12.0%)	(0.056)
HPV DNA				
Negative	82 (70.1%)	49 (41.9%)	33 (28.2%)	9.543
Positive	35 (29.9%)	10 (8.5%)	25 (21.4%)	(0.002)
HPV mRNA ISH				
Negative	87 (74.4%)	51 (43.6%)	36 (30.8%)	9.112
Positive	30 (25.6%)	8 (6.8%)	22 (18.8%)	(0.003)
p53/p16				
p53+/p16-	54 (46.2%)	34 (29.1%)	20 (17.1%)	7.891
p53-/p16+	34 (29.1%)	11 (9.4%)	23 (19.7%)	(0.019)
p53-/p16-	29 (24.8%)	14 (12.0%)	15 (12.8%)	
Recurrence of cancer				
No	79 (67.5%)	35 (29.9%)	44 (37.6%)	3.649
Yes	38 (32.5%)	24 (20.5%)	14 (12.0%)	(0.056)
Death caused by VSCC				
No	94 (80.3%)	46 (39.3%)	48 (41.0%)	0.425
Yes	23 (19.7%)	13 (11.1%)	10 (8.5%)	(0.514)

764